HUE065746T2 - Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére - Google Patents

Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Info

Publication number
HUE065746T2
HUE065746T2 HUE13836324A HUE13836324A HUE065746T2 HU E065746 T2 HUE065746 T2 HU E065746T2 HU E13836324 A HUE13836324 A HU E13836324A HU E13836324 A HUE13836324 A HU E13836324A HU E065746 T2 HUE065746 T2 HU E065746T2
Authority
HU
Hungary
Prior art keywords
preparations
treatment
methods
mycobacterium tuberculosis
tuberculosis infection
Prior art date
Application number
HUE13836324A
Other languages
English (en)
Hungarian (hu)
Inventor
Steven Reed
Rhea Coler
Original Assignee
Access To Advanced Health Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access To Advanced Health Inst filed Critical Access To Advanced Health Inst
Publication of HUE065746T2 publication Critical patent/HUE065746T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13836324A 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére HUE065746T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679612P 2012-08-03 2012-08-03
US201361791213P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE065746T2 true HUE065746T2 (hu) 2024-06-28

Family

ID=50278593

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13836324A HUE065746T2 (hu) 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Country Status (13)

Country Link
US (2) US20150182612A1 (enExample)
EP (2) EP4299138A3 (enExample)
JP (1) JP2015525784A (enExample)
CN (1) CN104812404A (enExample)
BR (1) BR112015002483A2 (enExample)
ES (1) ES2969734T3 (enExample)
HR (1) HRP20240164T1 (enExample)
HU (1) HUE065746T2 (enExample)
MX (1) MX385774B (enExample)
PT (1) PT2879701T (enExample)
RU (1) RU2659149C2 (enExample)
WO (1) WO2014042780A1 (enExample)
ZA (2) ZA201501242B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
RU2262950C2 (ru) * 2001-03-23 2005-10-27 Каунсил Оф Сайентифик Энд Индастриал Рисерч Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
EP1877426B1 (en) * 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
WO2007092590A2 (en) * 2006-02-08 2007-08-16 Fasgen, Inc. Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
WO2010010178A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
JP2012503206A (ja) * 2008-09-22 2012-02-02 オレゴン ヘルス アンド サイエンス ユニバーシティ Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EA201390424A1 (ru) * 2010-09-20 2013-07-30 Круселл Холланд Б.В. Терапевтическая вакцинация против активного туберкулеза

Also Published As

Publication number Publication date
EP2879701A4 (en) 2016-01-20
ZA201501242B (en) 2017-08-30
CN104812404A (zh) 2015-07-29
RU2015107435A (ru) 2016-09-27
JP2015525784A (ja) 2015-09-07
PT2879701T (pt) 2024-02-12
EP4299138A2 (en) 2024-01-03
WO2014042780A1 (en) 2014-03-20
ES2969734T3 (es) 2024-05-22
ZA201702091B (en) 2018-12-19
MX2015001557A (es) 2015-10-08
MX385774B (es) 2025-03-18
US20150182612A1 (en) 2015-07-02
RU2659149C2 (ru) 2018-06-28
EP2879701B1 (en) 2023-11-15
EP4299138A3 (en) 2024-08-14
US11369672B2 (en) 2022-06-28
EP2879701A1 (en) 2015-06-10
HRP20240164T1 (hr) 2024-04-12
US20200038498A1 (en) 2020-02-06
BR112015002483A2 (pt) 2017-11-07

Similar Documents

Publication Publication Date Title
IL284506B (en) Biological markers and signatures for diagnosing infections and methods for their use
HUE065746T2 (hu) Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
IL251647A0 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
IL283432A (en) Compositions, methods and systems for the treatment of cutaneous disorders
HUE058731T2 (hu) Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
HUE046292T2 (hu) Melanóma kezelése és diagnosztizálása
HUE047782T2 (hu) Gyógyászatilag aktív vegyületek és alkalmazási eljárásaik
ZA201408119B (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
HUE036561T2 (hu) Készítmények rheumatoid arthritis kezelésére és eljárások alkalmazására
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
HUE044778T2 (hu) Humán RPE sejt gyógyászati készítmények és alkalmazásaik
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
EP2800590C0 (en) SLOTTED AND SIDE-OPENING CATHETER DEVICES
IL235130A0 (en) Compositions for topical treatment of microbial infections
HUE049569T2 (hu) Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
HUE036930T2 (hu) Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IL237173B (en) Methods for treating hepatitis b and hepatitis d infections
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
IL234606B (en) Novel methods and composition for treatment of disease
EP3065674A4 (en) Monolithic medical devices and methods of use
HUE059757T2 (hu) Atazanavir és cobicistat formulációja HIV kezelésére
GB201201918D0 (en) Methods and devices for diagnosis of serious bacterial infection